Key Points
- Director Raymond Anderson sold 3,142 Monopar Therapeutics shares at an average price of $111.77, generating $351,181.34. The transaction, conducted under a pre-arranged Rule 10b5-1 plan, reduced his direct ownership by 11.68% to 23,751 shares.
- Monopar shares opened at $113.94, near their 52-week high of $124.82, with a market capitalization of approximately $764.5 million. The company recently reported a quarterly loss of $0.62 per share, narrowly beating analyst estimates.
- Analyst sentiment remains a “Moderate Buy”, with an average price target of $118.67, although several firms recently downgraded the stock to neutral, hold, or sell.
Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) Director Raymond Anderson sold 3,142 shares of Monopar Therapeutics stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $111.77, for a total value of $351,181.34. Following the completion of the transaction, the director directly owned 23,751 shares in the company, valued at $2,654,649.27. This represents a 11.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Monopar Therapeutics Stock Performance
MNPR opened at $113.94 on Friday. The firm has a 50 day moving average price of $105.56 and a 200 day moving average price of $74.74. The company has a market cap of $764.54 million, a PE ratio of -52.51 and a beta of 1.47. Monopar Therapeutics Inc. has a 1 year low of $32.77 and a 1 year high of $124.82.
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.02. On average, sell-side analysts predict that Monopar Therapeutics Inc. will post -2.94 earnings per share for the current year.
Institutional Trading of Monopar Therapeutics
Several large investors have recently bought and sold shares of the company. Russell Investments Group Ltd. purchased a new stake in shares of Monopar Therapeutics during the third quarter valued at approximately $28,000. BNP Paribas Financial Markets boosted its stake in shares of Monopar Therapeutics by 100.6% in the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company's stock valued at $57,000 after purchasing an additional 349 shares during the period. Sei Investments Co. boosted its stake in shares of Monopar Therapeutics by 9.5% in the first quarter. Sei Investments Co. now owns 7,582 shares of the company's stock valued at $415,000 after purchasing an additional 656 shares during the period. Meeder Asset Management Inc. acquired a new stake in Monopar Therapeutics during the 4th quarter valued at $65,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Monopar Therapeutics during the 4th quarter valued at $86,000. Institutional investors and hedge funds own 1.83% of the company's stock.
Analyst Ratings Changes
A number of equities analysts have recently commented on MNPR shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. Cantor Fitzgerald cut shares of Monopar Therapeutics from an "overweight" rating to a "neutral" rating and upped their price target for the stock from $109.00 to $119.00 in a research report on Thursday, August 13th. HC Wainwright increased their price target on Monopar Therapeutics from $105.00 to $125.00 and gave the company a "buy" rating in a report on Wednesday, July 22nd. Wall Street Zen lowered Monopar Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, August 16th. Finally, Zacks Research cut Monopar Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Monopar Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $118.67.
Read Our Latest Analysis on Monopar Therapeutics
About Monopar Therapeutics
(
Get Free Report)
Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.
The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
